Literature DB >> 9712193

Affinity profiles of novel delta-receptor selective benzofuran derivatives of non-peptide opioids.

M Spetea1, S T Nevin, S Hosztafi, A Z Rónai, G Tóth, A Borsodi.   

Abstract

Highly selective heterocyclic opioid ligands with potent delta-antagonist activity have been developed on the basis of the "message-address" concept. Using this strategy, benzofuran derivatives corresponding to the non-selective opioid antagonist, naloxone, and to the mu-opioid receptor selective agonists, oxymorphone and oxycodone, were synthesized. In vitro opioid receptor binding profiles and agonist/antagonist character of these compounds were determined in rat brain membrane preparations with highly selective radioligands. All three benzofuran derivatives displayed high affinities for the delta-opioid receptor, much less potency toward the mu-binding site, and were the least effective at the kappa-site. The results indicated that the addition of the bezofuran moiety to these fused ring opioids confers delta-receptor selectivity. The Na+ indices suggested a partial agonist character for oxymorphone- and oxycodone-benzofuran, and an antagonist character for naloxone-benzofuran. These compounds were capable of irreversible inhibition of opioid binding sites in a dose-dependent.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9712193     DOI: 10.1023/a:1020738304036

Source DB:  PubMed          Journal:  Neurochem Res        ISSN: 0364-3190            Impact factor:   3.996


  27 in total

1.  A high affinity, highly selective ligand for the delta opioid receptor: [3H]-[D-Pen2, pCl-Phe4, d-Pen5]enkephalin.

Authors:  L K Vaughn; R J Knapp; G Toth; Y P Wan; V J Hruby; H I Yamamura
Journal:  Life Sci       Date:  1989       Impact factor: 5.037

Review 2.  Selective naltrexone-derived opioid receptor antagonists.

Authors:  A E Takemori; P S Portoghese
Journal:  Annu Rev Pharmacol Toxicol       Date:  1992       Impact factor: 13.820

Review 3.  Selective opioid receptor agonists and antagonists: research tools and potential therapeutic agents.

Authors:  D M Zimmerman; J D Leander
Journal:  J Med Chem       Date:  1990-03       Impact factor: 7.446

4.  Application of the message-address concept in the design of highly potent and selective non-peptide delta opioid receptor antagonists.

Authors:  P S Portoghese; M Sultana; H Nagase; A E Takemori
Journal:  J Med Chem       Date:  1988-02       Impact factor: 7.446

5.  [3H]U-69593 a highly selective ligand for the opioid kappa receptor.

Authors:  R A Lahti; M M Mickelson; J M McCall; P F Von Voigtlander
Journal:  Eur J Pharmacol       Date:  1985-02-26       Impact factor: 4.432

6.  Characterization of opioid receptors in nervous tissue.

Authors:  H W Kosterlitz; S J Paterson
Journal:  Proc R Soc Lond B Biol Sci       Date:  1980-10-29

7.  Binding characteristics of the novel highly selective delta agonist, [3H]IIe5,6deltorphin II.

Authors:  S T Nevin; L Kabasakal; F Otvös; G Töth; A Borsodi
Journal:  Neuropeptides       Date:  1994-04       Impact factor: 3.286

8.  Opioid receptor labeling with the chloromethyl ketone derivative of (3)H-Tyr-D-Ala-Gly-(Me)Phe-Gly-ol (DAMGO) I: Binding properties of 3H-Tyr-D-Ala-Gly-(Me)Phe chloromethyl.

Authors:  H A Oktem; E Varga; J Hepp; K Medzihradzky; A Lajtha; A Borsodi
Journal:  Life Sci       Date:  1991       Impact factor: 5.037

9.  Characterization of [3H]naltrindole binding to delta opioid receptors in rat brain.

Authors:  M S Yamamura; R Horvath; G Toth; F Otvos; E Malatynska; R J Knapp; F Porreca; V J Hruby; H I Yamamura
Journal:  Life Sci       Date:  1992       Impact factor: 5.037

10.  Analogues of beta-LPH61-64 possessing selective agonist activity at mu-opiate receptors.

Authors:  B K Handa; A C Land; J A Lord; B A Morgan; M J Rance; C F Smith
Journal:  Eur J Pharmacol       Date:  1981-04-09       Impact factor: 4.432

View more
  4 in total

1.  Oxycodone lengthens reproductions of suprasecond time intervals in human research volunteers.

Authors:  Cynthia M Gooch; Brian C Rakitin; Ziva D Cooper; Sandra D Comer; Peter D Balsam
Journal:  Behav Pharmacol       Date:  2011-08       Impact factor: 2.293

2.  In vitro and in vivo characterization of A-796260: a selective cannabinoid CB2 receptor agonist exhibiting analgesic activity in rodent pain models.

Authors:  B B Yao; G C Hsieh; J M Frost; Y Fan; T R Garrison; A V Daza; G K Grayson; C Z Zhu; M Pai; P Chandran; A K Salyers; E J Wensink; P Honore; J P Sullivan; M J Dart; M D Meyer
Journal:  Br J Pharmacol       Date:  2007-11-12       Impact factor: 8.739

3.  Role of µ, κ, and δ opioid receptors in tibial inhibition of bladder overactivity in cats.

Authors:  Zhaocun Zhang; Richard C Slater; Matthew C Ferroni; Brian T Kadow; Timothy D Lyon; Bing Shen; Zhiying Xiao; Jicheng Wang; Audry Kang; James R Roppolo; William C de Groat; Changfeng Tai
Journal:  J Pharmacol Exp Ther       Date:  2015-09-09       Impact factor: 4.030

4.  In vitro and in vivo pharmacological profile of the 5-benzyl analogue of 14-methoxymetopon, a novel mu opioid analgesic with reduced propensity to alter motor function.

Authors:  Mariana Spetea; Catalina R Bohotin; Muhammad F Asim; Kurt Stübegger; Helmut Schmidhammer
Journal:  Eur J Pharm Sci       Date:  2010-06-18       Impact factor: 4.384

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.